Barbara Girerd
Overview
Explore the profile of Barbara Girerd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
3891
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gerges C, Beurnier A, Jais X, Herve P, Lau E, Girerd B, et al.
Chest
. 2024 Jul;
166(5):1173-1183.
PMID: 39059577
Background: Exercise hemodynamics are recommended for early detection of pulmonary arterial hypertension (PAH) and have been suggested to be predictive of future development of PAH in high-risk populations such as...
2.
Boros E, Ertl D, Berkenou J, Audrain C, Lecoq A, Kamenicky P, et al.
Eur J Endocrinol
. 2023 Oct;
189(4):469-475.
PMID: 37831782
Objectives: The aim of this study is to analyze height after cessation of growth (final height [FH]) and its evolution over the last decades in X-linked hypophosphatemia (XLH) patients in...
3.
Prapa M, Lago-Docampo M, Swietlik E, Montani D, Eyries M, Humbert M, et al.
Am J Respir Crit Care Med
. 2022 Jul;
206(12):1522-1533.
PMID: 35852389
Despite the increased recognition of (T-BOX transcription factor 4)-associated pulmonary arterial hypertension (PAH), genotype-phenotype associations are lacking and may provide important insights. To compile and functionally characterize all variants reported...
4.
Lechartier B, Girerd B, Eyries M, Beurnier A, Humbert M, Montani D
Eur Respir J
. 2022 Jun;
60(2).
PMID: 35710265
No abstract available.
5.
Montani D, Lechartier B, Girerd B, Eyries M, Ghigna M, Savale L, et al.
Eur Respir J
. 2022 May;
60(6).
PMID: 35618278
Background: The phenotype of pulmonary arterial hypertension (PAH) patients carrying pathogenic variants remains mostly unknown. Methods: We report the genetic analysis findings, characteristics and outcomes of patients with heritable PAH...
6.
Harbaum L, Rhodes C, Wharton J, Lawrie A, Karnes J, Desai A, et al.
Am J Respir Crit Care Med
. 2022 Apr;
205(12):1449-1460.
PMID: 35394406
Pulmonary arterial hypertension (PAH) is characterized by structural remodeling of pulmonary arteries and arterioles. Underlying biological processes are likely reflected in a perturbation of circulating proteins. To quantify and analyze...
7.
Le Ribeuz H, Masson B, Capuano V, Dutheil M, Gooroochurn H, Boet A, et al.
Am J Respir Cell Mol Biol
. 2022 Feb;
66(5):539-554.
PMID: 35175177
Mutations in have been identified in pulmonary arterial hypertension (PAH). encodes SUR1, a regulatory subunit of the ATP-sensitive potassium channel Kir6.2. However, the pathophysiological role of the SUR1/Kir6.2 channel in...
8.
Rhodes C, Wharton J, Swietlik E, Harbaum L, Girerd B, Coghlan J, et al.
Am J Respir Crit Care Med
. 2022 Jan;
205(9):1102-1111.
PMID: 35081018
NT-proBNP (N-terminal pro-brain natriuretic peptide), a biomarker of cardiac origin, is used to risk stratify patients with pulmonary arterial hypertension (PAH). Its limitations include poor sensitivity to early vascular pathology....
9.
Cheron C, McBride S, Antigny F, Girerd B, Chouchana M, Chaumais M, et al.
Eur Respir Rev
. 2021 Nov;
30(162).
PMID: 34750113
Pulmonary arterial hypertension (PAH) is a rare disease characterised by pulmonary vascular remodelling and elevated pulmonary pressure, which eventually leads to right heart failure and death. Registries worldwide have noted...
10.
Eyries M, Girerd B, Savale L, Soubrier F, Humbert M, Montani D
Clin Genet
. 2021 Aug;
100(6):771-772.
PMID: 34435352
No abstract available.